Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773655 · ClinicalTrials.gov registry record
Clinical and Histopathologic Characteristics of BAP1 Mutations
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 196
- Enrollment target
NCT01773655: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01773655 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 196 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773655 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 196 participants
- Enrollment target
Study Summary
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen at our institution.
Interventions
- OTHER tumor specimens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2013-01 |
| Est. Completion | 2020-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01773655
The ClinicalTrials.gov registry entry for NCT01773655 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tumor specimens is the first listed.
NCT01773655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01773655 about?
NCT01773655 is a clinical study titled "Clinical and Histopathologic Characteristics of BAP1 Mutations". The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen at our institution.
What is the current status of trial NCT01773655?
This trial is currently completed. The enrollment target is 196 participants. The study started on 2013-01. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT01773655?
The interventions under investigation include: tumor specimens (OTHER).
Who is sponsoring clinical trial NCT01773655?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.